Explore more publications!
Science & Tech Daily Nauru
Got News to Share?

Science & Tech Daily Nauru: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science & Tech Daily Nauru.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 10, 2025

24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business
December 10, 2025

24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business

Indeterminate GlobeNewswire
BLOX Markets Integrates Aeron® by Adaptive to Power its Upcoming Retail-Focused U.S. Equities Trading Venue
December 10, 2025

BLOX Markets Integrates Aeron® by Adaptive to Power its Upcoming Retail-Focused U.S. Equities Trading Venue

Indeterminate GlobeNewswire
Acquia Releases Next Generation SaaS CMS with Built-In AI Agents
December 10, 2025

Acquia Releases Next Generation SaaS CMS with Built-In AI Agents

Indeterminate GlobeNewswire
Lightrun ‘Runtime Context’ Empowers AI Coding Agents to Build Software That Works in the Real World
December 10, 2025

Lightrun ‘Runtime Context’ Empowers AI Coding Agents to Build Software That Works in the Real World

Indeterminate GlobeNewswire
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
December 10, 2025

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

Indeterminate GlobeNewswire
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
December 10, 2025

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Indeterminate GlobeNewswire
BlockQuarry Announces Launch of New Corporate Website, BLQCBuster.com
December 10, 2025

BlockQuarry Announces Launch of New Corporate Website, BLQCBuster.com

Indeterminate GlobeNewswire
authID’s PrivacyKey™ Named “Best Digital Trust Solution - ID Verification & Authentication” in 2025 PayTech Awards
December 10, 2025

authID’s PrivacyKey™ Named “Best Digital Trust Solution - ID Verification & Authentication” in 2025 PayTech Awards

Indeterminate GlobeNewswire
Youxin Technology Receives 2025 Hong Kong Innovation Leadership Award
December 10, 2025

Youxin Technology Receives 2025 Hong Kong Innovation Leadership Award

Indeterminate GlobeNewswire
EagleNXT MicaSense Cameras Now Compatible with Inspired Flight Technologies (IFT) new “Dovetail” Mount
December 10, 2025

EagleNXT MicaSense Cameras Now Compatible with Inspired Flight Technologies (IFT) new “Dovetail” Mount

Indeterminate GlobeNewswire
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
December 10, 2025

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Indeterminate GlobeNewswire
Genius Group Executes Fourth Buyback of One Million Shares
December 10, 2025

Genius Group Executes Fourth Buyback of One Million Shares

Indeterminate GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Indeterminate GlobeNewswire
Xtract One Secures SmartGateway Contract with Leading Nationwide Healthcare Provider to Bolster Safety at Clinics Across the Midwest
December 10, 2025

Xtract One Secures SmartGateway Contract with Leading Nationwide Healthcare Provider to Bolster Safety at Clinics Across the Midwest

Indeterminate GlobeNewswire
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
December 10, 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Indeterminate GlobeNewswire
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
December 10, 2025

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Indeterminate GlobeNewswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
December 10, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Indeterminate GlobeNewswire
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
December 10, 2025

Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray

Indeterminate GlobeNewswire
sensiBel Eval Kits Accelerate Applications of World’s First Studio-quality Optical MEMS Microphone
December 10, 2025

sensiBel Eval Kits Accelerate Applications of World’s First Studio-quality Optical MEMS Microphone

Indeterminate GlobeNewswire
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 10, 2025

Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions